| Mrs Darcy Woertink, CSW-PIP | |
|
401 9th Ave Nw, Watertown, SD 57201-1548 | |
| (605) 882-7000 | |
| Not Available |
| Full Name | Mrs Darcy Woertink |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 401 9th Ave Nw, Watertown, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720438344 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (South Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Darcy Woertink, CSW-PIP 401 9th Ave Nw, Watertown, SD 57201-1548 Ph: (605) 882-7000 | Mrs Darcy Woertink, CSW-PIP 401 9th Ave Nw, Watertown, SD 57201-1548 Ph: (605) 882-7000 |
News Archive
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ELIQUIS® (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia. Their findings should prove useful in treating patients by providing a molecular target against which to develop new drugs against one subset of AML as well as other cancers.
Biovista Inc. today announced that the U.S. Food and Drug Administration (FDA) has licensed its technology platform to help analyze, identify, and better understand the way certain drugs can cause harmful side effects.
A close collaboration between researchers at the Salk Institute for Biological Studies and the Institute for Advanced Study found that the tumor suppressor p53, long thought of as the "Guardian of the Genome," may do more than thwart cancer-causing mutations. It may also prevent established cancer cells from sliding toward a more aggressive, stem-like state by serving as a "Guardian against Genome Reprogramming."
› Verified 3 days ago
Heather Tobin, CSW-PIP Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 123 19th St Ne, Watertown, SD 57201 Phone: 605-886-0123 Fax: 605-886-5447 | |
Sarah Jo Dykstra, MSW-PIP Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 600 4th St Ne Ste 203, Watertown, SD 57201 Phone: 605-886-5262 Fax: 605-886-5228 | |
Dr. Melinda J Yexley, PHD Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 123 19th St Ne, Watertown, SD 57201 Phone: 605-886-0123 Fax: 605-886-5447 | |
David Evan Mendel, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 123 19th St Ne, Watertown, SD 57201 Phone: 605-886-0123 Fax: 605-886-5447 | |
Jani L Moran, CSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 600 4th St Ne Ste 203, Watertown, SD 57201 Phone: 605-886-5262 Fax: 605-886-5228 | |
Rachael Renee Stangeland, MSW-PIP Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 600 4th St Ne Ste 203, Watertown, SD 57201 Phone: 605-886-5262 Fax: 605-886-5228 | |
Mrs. Eloise Joan Falk, M ED LPC NCC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 123 19th Street Ne, Watertown, SD 57201 Phone: 605-886-0123 Fax: 605-886-5447 |